Abstract
The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.
Current Drug Safety
Title:Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Gianluca Moroncini, Lisa Albani, Lorenzo Nobili and Armando Gabrielli
Affiliation:
Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.
Abstract: The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Export Options
About this article
Cite this article as:
Moroncini Gianluca, Albani Lisa, Nobili Lorenzo and Gabrielli Armando, Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115251
DOI https://dx.doi.org/10.2174/1574886310666151014115251 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Editorial [Hot Topic: The Eye in Rheumatological Disease (Guest Editors: Sue Lightman and Simon Taylor)]
Current Rheumatology Reviews Regulation of Platelet Function by Acetylation/Deacetylation Mechanisms
Current Medicinal Chemistry Vincristine-Induced Seizure Potentiated by Itraconazole Following RCHOP Chemotherapy for Diffuse Large B-Cell Lymphoma
Current Drug Safety Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors
Current Cardiology Reviews The Role of Nitric Oxide on Endothelial Function
Current Vascular Pharmacology Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications
Coronaviruses Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Review of the Biological Activity of Maslinic Acid
Current Drug Targets Practical Approach to Children Presenting with Eosinophila and Hypereosinophilia
Current Pediatric Reviews Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Oncolytic Virotherapy for Breast Cancer Treatment
Current Gene Therapy Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms
Current HIV Research Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling
Current Pharmaceutical Design The Physicochemical and Pharmacokinetic Relationships of Barbiturates – From the Past to the Future
Current Pharmaceutical Design Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design